MCL Literature Feed
17 papers on mantle cell lymphoma from PubMed. Updated daily.
This meta-analysis suggests zanubrutinib monotherapy yields superior complete and overall response rates over ibrutinib and acalabrutinib in relapsed/refractory MCL, informing optimal BTKi selection.
This meta-analysis quantifies the high incidence of neurotoxicity (ICANS) with brexucabtagene autoleucel in MCL, finding 61% of patients experience any grade and 33% experience severe events.
A matching-adjusted indirect comparison suggests pirtobrutinib improves survival versus standard of care for relapsed/refractory MCL patients who have progressed on a prior covalent BTKi, supporting its use.
This indirect treatment comparison provides the first comparative evidence between zanubrutinib and acalabrutinib for relapsed/refractory MCL, guiding clinical selection in the absence of a head-to-head trial.
A pooled analysis of six phase 3 trials shows median overall survival for young, fit MCL patients improved from 4.9 years to not reached, driven by intensified frontline chemoimmunotherapy and transplant.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.
An updated indirect comparison suggests zanubrutinib provides significantly longer progression-free survival than orelabrutinib in relapsed/refractory MCL, informing BTKi choice in the absence of head-to-head trial data.
This meta-analysis of tirabrutinib monotherapy in relapsed/refractory B-cell lymphomas, including MCL, shows a pooled 72.5% overall response rate with manageable neutropenia and skin-related toxicities.
This systematic review of brexu-cel for relapsed/refractory MCL reveals conflicting cost-effectiveness conclusions across different countries, highlighting major uncertainties for health systems considering its adoption and reimbursement.
This meta-analysis quantifies the poor prognosis (median OS ~9 months) for r/r MCL patients post-covalent BTKi treated with standard therapies, highlighting the superior efficacy of brexucabtagene autoleucel.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A meta-analysis of 7,604 patients found mantle cell lymphoma has the highest non-relapse mortality (10.6%) post-CAR-T, with infections being the primary cause, not CAR-T-specific toxicities.
This meta-analysis of phase 2/3 trials quantifies venous thromboembolism risk after CAR-T therapy, providing crucial data to guide thromboprophylaxis strategies in MCL patients.
An indirect comparison suggests brexucabtagene autoleucel provides superior response rates and progression-free survival over pirtobrutinib for MCL patients who have failed a prior covalent BTKi.
This meta-analysis across B-NHLs confirms lenalidomide-based regimens improve OS and PFS, supporting its established role in relapsed/refractory and maintenance settings for MCL.
Mendelian randomization analysis reveals that genetically longer telomeres are a causal risk factor for developing hematological malignancies, including MCL, suggesting a potential inherited predisposition for the disease.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This meta-analysis of 984 R/R MCL patients confirms high CAR-T efficacy (74% CR, 69% 1-year OS), providing robust, pooled outcome data for this heavily pretreated population.
This indirect comparison shows acalabrutinib has a superior safety profile to ibrutinib in relapsed/refractory MCL with similar efficacy, supporting its preferential use in this setting.